The pediatric preclinical testing program: description of models and early testing results.

摘要: Background The Pediatric Preclinical Testing Program (PPTP) is an initiative supported by the National Cancer Institute (NCI) to identify novel therapeutic agents that may have significant activity against childhood cancers. PPTP has established panels of cancer xenografts and cell lines be used for in vivo vitro testing. These include Wilms tumor, sarcomas (rhabdomyosarcoma, Ewing sarcoma, osteosarcoma), neuroblastoma, brain tumors (glioblastoma, ependymoma, medulloblastoma), rhabdoid (CNS renal), acute lymphoblastic leukemia (ALL). Here, we describe characteristics tumor report results evaluation two standard agents, vincristine cyclophosphamide. Procedures Solid were grown subcutaneously immune-deficient mice dimensions measured weekly. ALL inoculated intravenously human CD45-positive cells enumerated Results Vincristine-induced objective responses 6 24 (25%) cyclophosphamide-induced 18 28 (64%) solid models. Comparable assessments high levels these obtained using a growth delay (TGD) measure. Both induced regressions each models evaluated. Conclusions We 51 10 cyclophosphamide as having broad-spectrum activity. appear generally recapitulate specific cancers potential identifying clinical